TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Alpha Teknova, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.80−0.28 (-3.95%)
Close on Oct 19, 2026
- Market cap
- $364.72M
- P/E (TTM)
- –
- Dividend yield
- –
Alpha Teknova, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Lab Essentials [Member] | $31.04M | $28.88M | $28.80M | $31.77M | $27.18M | $21.24M | 76.6% | +7.5% |
| Clinical Solutions [Member] | $7.65M | $7.10M | $6.74M | $8.45M | $6.79M | $4.81M | 18.9% | +7.8% |
| Other [Member] | $1.83M | $1.77M | $1.15M | $1.20M | $1.39M | $953.00K | 4.5% | +3.5% |
| Sample Transport [Member] | – | – | – | $6.00K | $1.53M | $4.30M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| United States | $38.25M | $35.92M | $35.00M | $40.10M | $35.81M | $30.14M | 94.4% | +6.5% |
| International [Member] | $2.27M | $1.83M | $1.68M | $1.32M | $1.09M | $1.16M | 5.6% | +24.4% |
From the segment and revenue-disaggregation notes of Alpha Teknova's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.